Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Roberta M. B. Sarmento
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
Frontiers in Oncology
Cancer Research
Oncology
Related publications
Cisplatin Versus Carboplatin in Combination With Paclitaxel as Neoadjuvant Regimen for Triple Negative Breast Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients
Cancer Management and Research
Oncology
TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Adjuvant Rituximab, a Potential Treatment for the Young Patient With Graves Hyperthyroidism (RiGD): Study Protocol for a Single-Arm, Single-Stage, Phase II Trial
Yearbook of Paediatric Endocrinology
A microRNA Signature Associated With Pathological Complete Response to Novel Neoadjuvant Therapy Regimen in Triple-Negative Breast Cancer
Tumor Biology
Medicine
Cancer Research
P2-033Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Dose Dense in Stage III Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients
Oncologist
Cancer Research
Medicine
Oncology